Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.43 USD 2.65% Market Closed
Market Cap: 849.5m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Intangible Assets
$76.6m
CAGR 3-Years
6%
CAGR 5-Years
70%
CAGR 10-Years
15%
Pharming Group NV
AEX:PHARM
Intangible Assets
$67.1m
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
72%
ProQR Therapeutics NV
NASDAQ:PRQR
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Intangible Assets
$141.8m
CAGR 3-Years
-7%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Intangible Assets
$1.9m
CAGR 3-Years
-9%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
849.5m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's Intangible Assets?
Intangible Assets
76.6m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Intangible Assets amounts to 76.6m USD.

What is Uniqure NV's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
15%

Over the last year, the Intangible Assets growth was 32%. The average annual Intangible Assets growth rates for Uniqure NV have been 6% over the past three years , 70% over the past five years , and 15% over the past ten years .

Back to Top